Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Therapeutic management and adjustment of long-term treatment].

Revue des maladies respiratoires·2024
Same author

Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability.

Frontiers in pharmacology·2022
Same author

[Management of mild asthma in 2019-2020: What about new international therapeutic proposals (GINA 2019)?]

Revue des maladies respiratoires·2020
Same author

A marine-sourced fucoidan solution inhibits Toll-like-receptor-3-induced cytokine release by human bronchial epithelial cells.

International journal of biological macromolecules·2019
Same author

Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis.

Anaesthesia·2018
Same author

In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016

Related Experiment Video

Updated: May 24, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

[Asthma exacerbations: pharmacological prevention].

S Grassin-Delyle1, P-O Girodet

  • 1Laboratoire de pharmacologie pulmonaire, UPRES EA220, hôpital Foch, université Versailles--Saint-Quentin-en-Yvelines, Suresnes, France.

Revue Des Maladies Respiratoires
|March 13, 2012
PubMed
Summary

Inhaled corticosteroids (ICS) are the primary treatment for controlling asthma exacerbations and improving lung function. Combining ICS with long-acting beta-agonists (LABA) is recommended for persistent asthma not controlled by ICS alone.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: May 24, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

  • Respiratory Medicine
  • Clinical Pharmacology

Context:

  • Asthma exacerbations lead to significant healthcare utilization and costs.
  • Airway inflammation is central to asthma exacerbations, necessitating effective long-term control strategies.

Purpose:

  • To review current therapeutic strategies for managing asthma exacerbations.
  • To evaluate the efficacy of various asthma medications, including inhaled corticosteroids (ICS), leukotriene receptor antagonists, long-acting inhaled beta-agonists (LABA), and omalizumab.

Summary:

  • Inhaled corticosteroids (ICS) are first-line therapy, reducing exacerbations and improving lung function.
  • For inadequately controlled persistent asthma, adding a long-acting inhaled beta-agonist (LABA) to ICS is recommended; LABA should not be used as monotherapy.
  • Omalizumab is effective for severe allergic asthma, reducing exacerbations and emergency visits. Sputum inflammatory markers may guide therapy.
  • Comorbidities like gastro-oesophageal reflux and allergic rhinitis are common but their specific treatments do not reduce asthma exacerbation rates.

Impact:

  • Highlights the established role of ICS as foundational therapy for asthma control.
  • Provides guidance on add-on therapies like LABA and omalizumab for specific asthma phenotypes.
  • Emphasizes the importance of addressing comorbidities while noting limitations of certain treatments in reducing exacerbation frequency.